Telix Pharmaceuticals Limited: Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

Summary of Study Outcomes ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met all of its primary and secondary

Related Keywords

Australia ,Japan ,United States ,United Kingdom ,Belgium ,California ,Melbourne ,Victoria ,Canada ,Switzerland ,France ,Los Angeles ,Australian ,Gregory Jack ,Kyahn Williamson ,Colin Hayward ,Brian Shuch ,Telix Pharmaceuticals ,Linkedin ,Urological Surgeon Austin Health ,Drug Administration ,Institute Of Urologic Oncology Los Angeles ,Australian Securities Exchange ,Prnewswire Telix Pharmaceuticals Limited ,Australian Therapeutic Goods Administration ,Kidney Cancer Program ,Olivia Newton John Cancer Centre Melbourne ,Corporate Communications ,Health Canada ,Nuclear Medicine Department ,Biologics License Application ,Pharmaceuticals Limited ,Prof Brian Shuch ,Urologic Oncology ,General Urological Surgeon Austin Health ,Olivia Newton John Cancer Centre ,Chief Medical Officer ,Telix Pharmaceuticals Limited ,Telix ,Pharmaceuticals ,Imited ,Nnounces ,Positive ,Topline ,Results ,Zircon ,Hase ,Kidney ,Dancer ,Maging ,Study ,